These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20545592)

  • 1. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research.
    Kerr C; Nixon A; Wild D
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):269-81. PubMed ID: 20545592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
    Willke RJ; Burke LB; Erickson P
    Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life.
    Wiklund I
    Fundam Clin Pharmacol; 2004 Jun; 18(3):351-63. PubMed ID: 15147288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
    Bottomley A; Jones D; Claassens L
    Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.
    DeMuro C; Clark M; Mordin M; Fehnel S; Copley-Merriman C; Gnanasakthy A
    Value Health; 2012 May; 15(3):443-8. PubMed ID: 22583454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.
    Hao Y
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):407-20. PubMed ID: 20715918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims.
    Coons SJ; Kothari S; Monz BU; Burke LB
    Clin Pharmacol Ther; 2011 Nov; 90(5):743-8. PubMed ID: 21993428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.
    Cleeland CS; Sloan JA;
    J Pain Symptom Manage; 2010 Jun; 39(6):1077-85. PubMed ID: 20538189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Including patient-reported outcomes and patient-reported resource-use questionnaires in studies.
    Bresnahan BW; Rundell SD
    Acad Radiol; 2014 Sep; 21(9):1129-37. PubMed ID: 25107865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.
    Gondek K; Sagnier PP; Gilchrist K; Woolley JM
    J Clin Oncol; 2007 Nov; 25(32):5087-93. PubMed ID: 17991926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcome measures: the importance of patient satisfaction in surgery.
    Chow A; Mayer EK; Darzi AW; Athanasiou T
    Surgery; 2009 Sep; 146(3):435-43. PubMed ID: 19715800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper.
    Baiardini I; Bousquet PJ; Brzoza Z; Canonica GW; Compalati E; Fiocchi A; Fokkens W; van Wijk RG; La Grutta S; Lombardi C; Maurer M; Pinto AM; Ridolo E; Senna GE; Terreehorst I; Bom AT; Bousquet J; Zuberbier T; Braido F;
    Allergy; 2010 Mar; 65(3):290-5. PubMed ID: 19930232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring patient satisfaction in healthcare organizations: qualitative and quantitative approaches.
    Fottler MD; Ford RC; Bach SA
    Best Pract Benchmarking Healthc; 1997; 2(6):227-39. PubMed ID: 9543919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.
    Basch E
    Value Health; 2012 May; 15(3):401-3. PubMed ID: 22583448
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient-reported outcomes supporting anticancer product approvals.
    Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
    J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes (PROs) in dental clinical trials and product development: introduction to scientific and regulatory considerations.
    Gwaltney CJ
    J Evid Based Dent Pract; 2010 Jun; 10(2):86-90. PubMed ID: 20466315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sensitivity to change].
    Igl W; Zwingmann C; Faller H
    Rehabilitation (Stuttg); 2005 Apr; 44(2):100-6. PubMed ID: 15789293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capturing patients' perspectives of treatment in clinical trials/drug development.
    Hareendran A; Gnanasakthy A; Winnette R; Revicki D
    Contemp Clin Trials; 2012 Jan; 33(1):23-8. PubMed ID: 22001362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.